Anti-CRISPRs (Acrs) are small proteins that inhibit the RNA-guided DNA targeting activity of CRISPR-Cas enzymes. Encoded by bacteriophage and phage-derived bacterial genes, Acrs prevent CRISPR-mediated inhibition of phage infection and can also block CRISPR-Casmediated genome editing in eukaryotic cells. To identify Acrs capable of inhibiting Staphylococcus aureus Cas9 (SauCas9), an alternative to the most commonly used genome editing protein Streptococcus pyogenes Cas9 (SpyCas9), we used both self-targeting CRISPR screening and guilt-by-association genomic search strategies. Here we describe three new potent inhibitors of SauCas9 that we name AcrIIA13, AcrIIA14 and AcrIIA15. These inhibitors share a conserved N-terminal sequence that is dispensable for anti-CRISPR function, and have divergent C-termini that are required in each case for selective inhibition of SauCas9-catalyzed DNA cleavage. In human cells, we observe robust and specific inhibition of SauCas9-induced genome editing by AcrIIA13 and moderate inhibition by AcrIIA14 and AcrIIA15. We also find that the conserved N-terminal domain of AcrIIA13-15 binds to an inverted repeat sequence in the promoter of these Acr genes, consistent with its predicted helix-turn-helix DNA binding structure. These data demonstrate an effective strategy for Acr discovery and establish AcrIIA13-15 as unique bifunctional inhibitors of SauCas9.
Introduction
CRISPR systems are RNA-guided, adaptive immune systems that defend prokaryotes against invading mobile genetic elements (MGEs) (1) . However, some MGEs, particularly phages, have evolved anti-CRISPRs (Acrs), peptide inhibitors of Cas proteins that block CRISPR defense systems (2, 3) . Acrs have been discovered to inhibit distinct CRISPR systems, including type I (4) (5) (6) (7) (8) , type II (9) (10) (11) (12) (13) (14) (15) (16) , type III (17, 18) , and type V (7, 19) . Strategies for identifying new Acrs include testing genes of unknown function that are proximal to anti-CRISPR associated (aca) genes (5-7, 9, 15) and screening genes in organisms with self-targeting CRISPR systems (7, 19, 20) .
The frequent clustering of Acr and aca genes together allows for a 'guilt-by-association' approach that quickly identifies potential Acr candidates for experimental testing, but requires a known Acr or aca gene to seed the search (5-7, 9, 15) . Conversely, self-targeting CRISPR systems represent diverse genomes that could encode corresponding CRISPR-Cas inhibitors to block autoimmunity (21) (Fig. 1A) , but finding relevant Acr-encoding genes within these genomes can be daunting. Nonetheless, analysis of known Acrs suggests that self-targeting CRISPR-containing genomes are attractive to study because they often encode at least one corresponding Acr (19) .
Multiple anti-CRISPR (Acr) families inhibit Streptococcus pyogenes Cas9 (SpyCas9) and various Cas12a proteins, and can be used in cell-based experiments to control genome editing outcomes (7, 10, 11, 13, 14, 22, 23) . Although weak cross-reactivity with other non-cognate Cas9 orthologs has been detected for a subset of these, we wondered whether more potent and selective inhibitors of particular Cas9 variants might exist in nature. To address this question, we focused on Staphylococcus genomes that might encode inhibitors of Staphylococcus aureus Cas9 (SauCas9), a genome editing alternative to SpyCas9 whose smaller size could offer advantages for delivery into mammalian cells (24, 25) . We used a combination of self-targeting CRISPR screening and guilt-by-association genomic searches to discover three new peptide inhibitors of SauCas9. We show that these SauCas9 Acrs, AcrIIA13, AcrIIA14 and AcrIIA15, limit or prevent RNA-guided DNA cleavage in vitro and genome editing in human cells. These three inhibitors share a common N-terminal domain with a predicted helix-turn-helix structure that is dispensable for Acr function but can bind specifically to the inverted repeat sequence in the promoter of these Acr genes. The C-terminus of each Acr is distinct and is responsible for SauCas9 inhibition in each case, likely by differing mechanisms. These SauCas9 inhibitors provide new tools for the selective control of genome editing outcomes, and validate a multipronged strategy for discovering diverse Acrs in nature.
Results

Bioinformatic identification of self-targeting type II-A CRISPR systems
To identify potential new Acrs that inhibit SauCas9, we first used the Self-Target Spacer Searcher (STSS) (19) to query all Staphylococcus species deposited in NCBI for instances of CRISPR self-targeting. We observed 99 total instances of self-targeting in Staphylococcus CRISPR systems across 43 different strains out of a potential 11,910 assemblies searched (Table   S1 ). Of the 99 self-targeting instances predicted, 50 could not be attributed to any particular CRISPR subtype, 48 were associated with a type II-A system, and one occurred as part of a type III-A system. We did not observe any self-targeting CRISPR type I-C systems that are occasionally found in Staphylococcus (26) . It should also be noted that 29 of the predicted 5 CRISPR self-targeting systems occurred in eight species whose CRISPR loci were manually annotated as type II-A based on identity to other type II-A Cas9-encoding genes.
To select the genomes most likely to contain Acrs, we filtered the list of 48 self-targets to exclude those with target protospacer-adjacent motifs (PAMs) that were more than one indel/mutation away from the known 3′-NNGRR(T) PAM for SauCas9 (25) . This step eliminated genomes in which an incorrect PAM sequence could explain survival, without the need for Acrs. The remaining 14 self-targeting instances, belonging to 12 different strains (Table   S1 ), were ranked according to similarity of their encoded Cas9 and SauCas9 (Table S2 ). Of the seven Cas9s displaying high similarity to SauCas9 (>50% identity with blastp), two species, Staphylococcus haemolyticus and Staphylococcus schleiferi, were selected for further screening for Acrs active against SauCas9 based on strain availability.
Self-targeting screen for Acr activity
To reduce the sequence space to search for Acr genes, we selected only one of the two selftargeting strains identified for each species (S. schleiferi and S. haemolyticus), since the two strains of each respective species contained highly similar genomic sequences and MGE content.
The S. schleiferi strain 5909-02 was chosen for having three self-targets vs. the two self-targets present in strain 2713-03, and S. haemolyticus strain W_75, containing a single self-target, was selected arbitrarily over strain W_139 (Fig. S1 ).
To first assess whether the CRISPR systems in S. schleiferi and S. haemolyticus are active, we generated amplicons encoding the Cas9, Cas1, Cas2 and Csn2 of each system under their natural promoters and a plasmid expressing a single-guide RNA (sgRNA) for SauCas9 (27) .
Two versions of the sgRNA were designed, one targeting a superfolder GFP reporter (sfGFP) 6 and the other containing a non-targeting sequence. We co-expressed each amplicon with the targeting or control sgRNA-encoding plasmid, and a plasmid encoding sfGFP, in a cell-free transcription-translation extract (TXTL) (19, 28). We observed a strong reduction in sfGFP expression in the TXTL reaction mixtures expressing the targeting, but not the non-targeting, sgRNAs (Fig. 1C ). This result suggests that the native type II-A CRISPR systems in both S. schleiferi strain 5909-02 and S. haemolyticus strain W_75 are active.
Nearly all currently known Acrs can be found in MGE sequences, especially phages, highlighting their use as a CRISPR counter-defense mechanism (3). Therefore, we examined the genomes of both S. schleiferi and S. haemolyticus for integrated MGEs using PHASTER (29) and Islander (30) to identify potential hotspots that might harbor Acrs. We found four predicted MGEs in S. schleiferi strain 5909-02 and eight in the contigs of the S. haemolyticus strain W_75 assembly. We then designed 27 genome fragment (GF) amplicons in total covering all the predicted sequences, each up to ~10 kb, with the goal of best capturing complete operons wherever possible (Table S3 ). We then prepared TXTL reactions containing DNA encoding the sfGFP reporter, the sgRNA-encoding plasmid, a GF amplicon, and the associated Cas proteinencoding amplicon from the GF's source organism. By comparing GFP expression over time, we found that the presence of GF5 from S. schleiferi corresponded to nearly complete inhibition of Cas9-mediated sfGFP knockdown ( Fig. 2A ). We observed no inhibitory activity in the presence of any GFs derived from S. haemolyticus. S. schleiferi GF5 contains eight genes ( Fig. 2B ), most of which are predicted to be part of the lactose metabolic pathway. Genes 1 and 2, however, have no predicted function. We cloned each gene from GF5 into a heterologous plasmid under the control of a pTet promoter and repeated the TXTL assay with each cloned gene individually in place of the GF5 amplicon. We 7 observed that gene 2 alone produced the inhibitory effect previously observed with the complete GF5 ( Fig. 2C ). This gene was named AcrIIA13 to indicate its inhibition of a CRISPR type II-A system, in accord with standard Acr nomenclature (22) . There is also a homologous protein, AcrIIA13a, found within GF8, and although no inhibitory activity from GF8 was ever observed, when AcrIIA13a is expressed separately using the pTet expression plasmid, it does exhibit inhibitory activity ( Fig. 2D ).
'Guilt-by-association' identification of SauCas9 Acrs
We wondered whether AcrIIA13 or the neighboring gene in its operon (GF5 gene 1) might be associated with other Acrs, and whether these inhibitors might have the ability to block activity of the SauCas9 protein. We first searched AcrIIA13 homologs to find potential Acr candidates co-occurring with it ( Fig. S2A ). While we did find a truncated homolog missing the AcrIIA13 Nterminus, AcrIIA13b, we did not observe any new genes commonly found near AcrIIA13.
However, when we searched for homologs of GF5 gene 1, we found that they occur widely in bacteria ( Fig. S2B ), a typical hallmark of aca genes (6, 9, 10, 15) . We identified genes that frequently co-occur with GF5 gene 1 and selected them as an initial set of Acr candidates. Then, because many Acrs are clustered together, we also added genes that co-occurred with the initially chosen Acr candidates to create the final test set. This set of ten candidate Acr genes was cloned into the pTet expression plasmid for further analysis.
Each of the ten new candidate Acr genes was tested in the TXTL sfGFP depletion experiment, this time using SauCas9 expressed from a recombinant plasmid. After ten hours, we observed that TXTL reaction mixtures for two of the new Acr candidates, candidate 1 and candidate 10, expressed GFP levels that were significantly above the baseline ( Fig. 2E and S3 ). 8 Candidate 1, hereafter referred to as AcrIIA14, is phylogenetically associated with a close homolog of GF5 gene 1 and occurs in Staphylococcus simulans strain 19, which had previously passed the PAM filtering step for self-targeting Staphylococcus genomes and has a Cas9 closely related to SauCas9 (86% identical via blastp) (Table S2 ). Although candidate 10, hereafter referred to as AcrIIA15, does not occur in a CRISPR-self-targeting strain, a close homolog (80% identical via blastp) can be found in S. pseudintermedius strain 104N, which is self-targeting ( Fig. S2 , Table S1 ).
Reconstitution of Acr activity against SauCas9
To examine the inhibitory activity detected in the TXTL experiments with AcrIIA13-15, we purified each Acr protein and tested its ability to inhibit SauCas9-mediated double-stranded DNA (dsDNA) cleavage in vitro. We began by first assembling the SauCas9-sgRNA RNP complex, then added the individually purified Acr proteins and dsDNA target. Under these conditions, we observed near total inhibition of SauCas9 dsDNA cleavage at 20-fold molar excess of Acr relative to Cas9 RNP (Fig. 3A , left and Fig. S4A , top). As a negative control, we performed the same assay using BSA and AcrVA4 and observed no difference in cleavage activity of SauCas9 ( Fig. S4B ). To shed more light on the mechanism, we performed the SauCas9 in vitro cleavage experiments again, but added the Acr proteins before the addition of sgRNA. Adding the Acr protein before the sgRNA led to ~4-fold increase in inhibition by the Acr proteins, on par with the only currently known broad spectrum Acr for type II-A Cas9, We then performed RNA electrophoretic mobility shift assays (EMSA) to determine if the Acrs were able to prevent, or reverse, Cas9-sgRNA RNP formation. While AcrIIA13 and AcrIIA14 did not prevent RNP formation, the addition of AcrIIA15 before the sgRNA during complex formation eliminated the presence of the slow-migrating species corresponding to Cas9 RNP formation that is visible when the Acr is added after RNP complex formation (Fig. 3B ).
The lack of a mobility-shifted species when AcrIIA15 is added before sgRNA suggests that AcrIIA15 binds directly to Cas9 to prevent RNP formation rather than causing RNP disassembly.
Next, we performed EMSAs to evaluate the ability of the Acrs to prevent binding of the Cas9-sgRNA RNP to its target dsDNA. We found that both AcrIIA13 and AcrIIA15 inhibited dsDNA binding of Cas9, but only when added prior to the addition of target dsDNA. Interestingly, although AcrIIA14 completely inhibited Cas9 cleavage activity ( Fig. 3A) , it did not prevent Cas9 RNP from binding to its target. However, a super-shifted species was observed after the addition of AcrIIA14 and either before or after addition of dsDNA. This suggests that AcrIIA14 may act by binding the SauCas9 active site without impacting DNA binding, similar to the behavior of AcrIIC1 (31) . AcrIIA14 might also trigger complex dimerization to form an inactive conformation, similar to the mechanisms of AcrIIC3 (31, 32) or AcrVA4 (33) ( Fig. 3C ).
Altogether, these biochemical data suggest that each of the newly discovered Acrs inhibits SauCas9-mediated DNA cleavage by a different method.
AcrIIA13-15 share a N-terminal domain that binds an inverted repeat
To determine the level of sequence similarity between AcrIIA13-15, we performed a multiple sequence alignment with MUSCLE and observed a shared N-terminal domain across all three Acrs, which was absent in AcrIIA13b, a truncated homolog of AcrIIA13 found during the guiltby-association search (Fig. 3D) . The remaining C-terminus, however, was not closely related between AcrIIA13-15 ( Fig. S5A) . Given the apparently distinct mechanisms of inhibition for AcrIIA13-15 respectively, we suspected that the residues downstream of the shared N-terminus were responsible for the Acr activity. To test this, we cloned, expressed and purified truncated versions of all three Acrs with the shared N-termini removed (Fig. S5A ). In DNA cleavage assays with the purified C-terminal AcrIIA13-15 proteins, all the Acrs showed complete inhibition of Cas9 cleavage activity at ~5-fold molar excess whether added before or after Cas9-sgRNA RNP formation ( Fig. S5B ). We also observe strong inhibition of the C-terminal portion of AcrIIA13 in the TXTL sfGFP expression assay, while no inhibition was detected using the Nterminal domain alone ( Fig. S5C ). Overall, these data support the conclusion that the variable Cterminal domains of AcrIIA13-15 constitute the Acr activity of each protein. We also tested the truncated AcrIIA13-15 proteins for inhibition of SpyCas9 in an RNA-guided DNA cleavage assay, but observed no significant reduction in DNA cutting (Fig. S5D ).
The shared Acr N-terminal domain binds an inverted-repeat DNA sequence
On further sequence analysis of the homologous N-terminal section of AcrIIA13-15, we found they contain a conserved helix-turn-helix (HTH) motif ( Fig. 3D and Fig. S5A ). These HTH domains have been found in aca genes and were recently shown to repress their own transcription along with other Acrs in the same operon (16, 34) . These aca genes encode proteins that bind to promoter-proximal sequences containing two inverted repeats to block polymerase access. We observe inverted repeats (IR) proximal to the promoters driving transcription of the operons containing AcrIIA13-15 ( Fig. S5A ). To determine if AcrIIA13-15 are capable of binding to the promoter proximal IR sequences, we performed DNA EMSAs, combining each purified Acr protein with a FAM-labelled dsDNA sequence spanning the IRs in the promoter-proximal region of AcrIIA15 (Fig. S5B ). We found that AcrIIA13 and AcrIIA15 strongly interact with the promoter-proximal IR sequence, while AcrIIA14 only weakly interacted with it ( Fig. 3E ).
Mutating the IR sequence of the dsDNA substrate completely abolished the Acr-IR DNA interaction. To further assess if this interaction was mediated by the HTH motif, we repeated the DNA EMSA using the C-terminal AcrIIA15, where we failed to detect any interaction with the dsDNA IR-DNA substrate (Fig. S6C ). Together, these data suggest that, similar to AcrIIA1 (16), AcrIIA13-15 also are fusion proteins that link an anti-SauCas9 Acr with a DNA binding domain that is likely to regulate the expression of its own operon.
Inhibition of SauCas9-mediated genome editing in human cells
To assess the ability of AcrIIA13-15 to inhibit genome editing in the context of human cells, we designed a lentiviral validation system to express Cas9, an sgRNA, and an Acr protein from three different, stably integrated constructs ( Fig. 4A ). Using HEK-RT1 genome editing reporter cells (35, 36 ) -a monoclonal HEK293T-based cell line expressing a doxycycline-inducible GFP reporter -lentiviral constructs encoding the AcrIIA proteins or mTagBFP2, and SauCas9 or SpyCas9, were sequentially transduced and stable integrants selected. The resulting cell lines were then further transduced with a vector expressing a GFP-targeting or negative control sgRNA and an associated mCherry fluorescence marker. In this system, we observed a baseline of ~75% GFP-positive cells after induction in presence of a negative control sgRNA, which was reduced to near 0% by an on-target sgRNA disrupting GFP expression ( Fig. S7 ).
We next tested three known Acrs for their ability to inhibit SauCas9-mediated genome editing in mammalian cells, including the robust SpyCas9 inhibitor AcrIIA4 (10), the broadspectrum type II-A Cas9 inhibitor AcrIIA5 (12) and the species-specific Streptococcus thermophilus Cas9 inhibitor AcrIIA6 (12) . While AcrIIA4 prevented genome editing by SpyCas9 as expected (10), we found that it had no effect against SauCas9 (Fig. S8 ). Conversely, AcrIIA5 displayed strong inhibitory activity towards both SauCas9 and SpyCas9, while AcrIIA6 did not show any inhibition of either of the two Cas9s.
Similar genome editing inhibition experiments using AcrIIA13-15 showed that AcrIIA13 is a potent inhibitor of SauCas9, with near complete inhibition of GFP gene editing activity ( Fig.   4B and Fig. S9 ). However, in contrast to AcrIIA5, AcrIIA13 did not inhibit SpyCas9, making it the first Acr selective for SauCas9 to our knowledge, and further expanding the CRISPR-Cas modulation toolkit. Interestingly, the truncated form of AcrIIA13, which is substantially smaller, was equally effective at inhibiting SauCas9-mediated genome editing in human cells. The AcrIIA13b homolog that lacks the N-terminal DNA-binding domain showed a comparable trend of SauCas9 selective inhibition. Full-length AcrIIA14 also proved to be a potent inhibitor of SauCas9, although less robust than AcrIIA13, and removing its N-terminal domain had a larger impact on its inhibitory efficacy (Fig. 4C ). SpyCas9 was not affected by AcrIIA14. Finally, only AcrIIA15 demonstrated any activity toward SpyCas9-mediated genome editing, but its inhibition was minimal ( Fig. 4C) , showing that AcrIIA13-15 are potent and selective inhibitors for SauCas9.
Discussion
The potential role of anti-CRISPRs in regulating CRISPR-Cas gene editing in therapeutic applications has helped spur the discovery of over 40 different families of Acrs (3). However, creating 'designer' inhibitors for specific gene editors and editing scenarios is very challenging as Acr proteins are small and lack any sequence and structural conservation to use for direct identification of desired modalities. To overcome these problems, approaches such as screening 13 self-targeting genomes (7, 10, 19) or metagenomic DNA (13, 14) attempt to cast a wide net in the genomic space to identify novel Acr activities. A more direct method is to use a 'guilt-byassociation' search approach, which leverages the repeated observations that Acrs tend to coexist in similar operons and that the genomic neighborhood of several Acrs contain anti-CRISPR associated (aca) genes that are closely coupled with Acrs, and widespread in bacteria and MGEs.
In this work, we sought to identify potent inhibitors of SauCas9, a common SpyCas9 alternative. Using a combination of the methods described above, we identified three novel families of Acrs (AcrIIA13-15) that are potent inhibitors of SauCas9. Using biochemical approaches, we find that all three Acrs possess different mechanisms of Cas9 inhibition.
AcrIIA13 prevents SauCas9-mediated dsDNA cleavage activity by blocking DNA binding, while AcrIIA15 binds to SauCas9 to block RNP assembly (Figs. 3B, 3C ). Our data also show that AcrIIA14 does not interfere with SauCas9 binding to either RNA or dsDNA, but inhibits dsDNA cleavage activity at a potency comparable to AcrIIA13 and AcrIIA15. It is possible that AcrIIA14 either causes the SauCas9-sgRNA RNP to form higher order structures like AcrVA4 (33) or AcrIIC3 (31, 32) , or interacts with RNP to prevent cleavage but not binding like AcrIIC1 (31) . We also observed potent and SauCas9-specific inhibition by AcrIIA13 and AcrIIA14 in mammalian cells (Fig, 4 ). AcrIIA15 was able to inhibit both SpyCas9 and SauCas9 in human cells, but to a much lesser extent. Of the three Acrs, AcrIIA13 was the most potent inhibitor of SauCas9 in human cells.
In comparing the protein sequences between AcrIIA13-15, we observe that the N-termini of the Acrs possessed a highly conserved HTH motif ( Figs. 3D and S4A) . This motif is a prominent feature of aca genes, which were recently shown to negatively regulate the transcription of their own operon (16, 34) . The self-regulating activity of aca proteins was shown 14 to be mediated by a direct interaction between the HTH motif and promoter proximal sequences containing two inverted repeats (IR). Examining the promoter regions of AcrIIA13-15, we found that all of them also contain similar promoter-proximal IR sequences (Fig. S6A) , and that all three Acrs are able to bind to the IR sequences specifically and only when the N-terminal domain is present ( Fig. 3E and S6C) . The DNA binding activity of the N-terminal region also has little to no effect on Acr potency when removed from the protein in in vitro cleavage assays ( Fig. S5B -D) and no or only a minor effect in human cells depending on the Acr (Fig. 4B,C) . AcrIIA13 in particular is unaffected by the removal of its N-terminus, and represents a highly potent, SauCas9-specific inhibitor for use in mammalian contexts for regulating Cas9 activity.
Based on our data, the AcrIIA13-15 proteins we identified are likely fusions between three unique Acr proteins and a shared aca gene, which we name aca8. It is unclear how aca8 became fused with different Acr proteins, or what benefit a single protein would have over the split alternative. Regardless, the new aca8 gene provides another seed to search for further discoveries using the guilt-by-association approach. With the addition of yet more proteins, we increase the chances of finding new activities that are particularly attractive to biotechnology and therapeutic applications, such as catalytic Acrs that would have low delivery requirements for potent inhibition (37, 38). We believe that the search for more Acrs with potent and novel mechanisms of inhibition will continue to rapidly add new dimensions of control into the CRISPR toolbox.
Materials and Methods
Self-targeting strain selection. The bioinformatics search for self-targeting Staphylococcus strains was carried out in a similar manner as described in Watters, et al. (19) . Briefly, the Self-Targeting Spacer Searcher (STSS) (https://github.com/kew222/Self-Targeting-Spacer-Searcher) was used the NCBI database for all assemblies returned using a search of "Staphylococcus[organism] NOT phage NOT virus". Each assembly was checked for instances of self-targeting, which were reported along with details about the instance including: target site mutations, up/downstream target sequences, Cas genes found near the array of the self-targeting spacer, predicted CRISPR subtype based on repeats/Cas proteins, repeat sequences and conservation, etc. Systems that were output as ambiguous type II CRISPR systems were manually checked for: 1) repeat sequence similarity to other known loci, 2) presence of defining Cas proteins (i.e. Csn2 for II-A), and 3) alignment of Cas9 of the system in question to a set of type II-A, II-B, and II-C Cas9s to determine similarity. The final set of self-targeting instances found in Staphylococcus genomes on NCBI can be found in Table S1 . Strains were chosen for further study based on similarity of the downstream target site to the SauCas9 PAM (3′-NNGRR(T) ) and similarity of the self-targeting system's Cas9 to SauCas9 by blastp.
Guilt-by-association search. GF genes 1 and 2 (AcrIIA13) were used to query the NCBI protein database with blastp to identify homologs. Each homolog found was then manually surveyed for neighboring genes that were not found within the genome fragment amplicons tested with the TXTL sfGFP assay. This approach was repeated using any neighboring proteins to further locate their neighbors. Only alignments with an E-value < 0.001 were considered. The search was ended after 10 candidate proteins were identified. (Table S3) . Similarly, genomic fragment amplicons were prepared with PCR using the gDNA and primers listed in Table S3 . Acr candidates that were to be tested individually were cloned into a plasmid for use in TXTL.
To prepare the plasmids for TXTL, a 20 mL culture of E. coli containing one of the plasmids was grown to high density, then isolated across five preparations using the Monarch Table S5 . In vitro cleavage assays. All dsDNA cleavage assays were performed in a 1X Cleavage Buffer containing 20 mM HEPES-HCl, pH 7.5, 150 mM KCl, 10 mM MgCl2, 0.5 mM TCEP. sgRNA sequences synthesized by IDT were first refolded in 1X cleavage buffer by heating at 70°C for 5 min then cooling to room temperature. For all the cleavage assays involving SauCas9, reaction components were added in the following two ways: (1) SauCas9 and Acrs were complexed together, followed by sequential addition of sgRNA and dsDNA. (2) SauCas9 and sgRNA were complexed together, followed by addition of Acrs and dsDNA target. Each step of sequential additions in both reactions were preceded by incubation at 37°C for 10 min. All cleavage reactions were then quenched on completion with 2 µL of 6X Quenching Buffer containing 30% glycerol, 1.2% SDS, 250 mM EDTA. Cleavage products were read using a 1% agarose gel prestained with SYBRGold. All DNA/RNA sequences used for biochemical assays can be found in Table S6 .
Electrophoretic mobility shift assays. RNA EMSAs were performed by incubating SauCas9 and sgRNA in 1X cleavage buffer lacking MgCl2 in the presence or absence of 10-fold molar excess of different Acrs relative to SauCas9. The reactions were then incubated at 37°C for 10 mins and run on 6% TBE polyacrylamide gels for 1 hr at 50V. The gels were then visualized using SYBRGold stain. DNA EMSAs to evaluate binding of SauCas9 RNP to dsDNA target were performed by incubating the reaction components described in their respective figures in 1X cleavage buffer lacking MgCl2 at 37°C for 10 min. The dsDNA substrates used for this assay were synthesized as 5' FAM labelled 34 bp DNA oligos that were annealed prior to their addition to the EMSA reaction. The reactions were run on 6% TBE polyacrylamide gels and visualized on a Typhoon imager (GE). DNA EMSAs for the binding of AcrIIA13-15 to IR DNA were performed by incubating the components in 1X cleavage buffer lacking MgCl2 at 37°C for 10 min. The completed reactions were then run on 6% TBE polyacrylamide gels for 1 hr at 50V and visualized with SYBRGold stain. vector pCF820, encoding a SpyCas9 U6-sgRNA cassette and an EF1a driven, human codon optimized mCherry2 marker (40) , was based on the pCF221 vector (35) . To make the backbone more efficient and increase viral titers, the f1 bacteriophage origin of replication and bleomycin resistance marker were removed, as has previously been done for pCF525 (19) . The SauCas9 guide RNA-only lentiviral vector pCF824, encoding an SauCas9 U6-sgRNA cassette and an EF1a driven, human codon optimized mCherry2 marker, was based on the pCF820 vector. The SauCas9 guide RNA scaffold was designed as previously reported (41) , synthesized as custom oligonucleotides (IDT), and assembled using Gibson techniques and standard molecular cloning methods. A lentiviral vector referred to as pCF823, expressing an EFS driven SpyCas9-P2A-PuroR cassette, was based on the vector pCF204 (35) by removing the f1 bacteriophage origin of replication and bleomycin resistance marker to increase viral titers. A lentiviral vector referred to as pCF825, expressing an EFS driven SauCas9-P2A-PuroR cassette, was based on the vector pCF823 by replacing the SpyCas9 ORF with the SauCas9 ORF from pX601 (Addgene #61591) (25) . Vector sequences are provided in a separate file (Table S7) .
Design of sgRNAs.
The following protospacer sequences were used for SpyCas9 sgRNAs: sgC (GGAGACGGAGGACGACGAACGTCTCT), sgGFP8 (GCAGGGTCAGCTTGCCGTAGG).
The following sequences were used for SauCas9 sgRNAs: sgC (GGAGACGGAGGACGACGAACGTCTCT), sgGFP1 (GCAAGGGCGAGGAGCTGTTCAC). inhibits SauCas9. (D) AcrIIA13a, a homolog of AcrIIA13, is found in GF8 and is also able to inhibit SauCas9 in a TXTL assay. GF8, which contains AcrIIA13a did not exhibit Acr activity, however. (E) Of 10 candidates chosen from a guilt-by-association search seeded by GF5 gene 1 (aca8), candidates 1 (AcrIIA14) and 10 (AcrIIA15) were found to inhibit SauCas9 using the TXTL assay. 
